Significantly reduced tumor burden and enhanced tumor-free survival after anti–CD19-MUC1 plus CpG immunization in MUC1 Tg mice. (A) MUC1 Tg mice were vaccinated with isotype mAb-MUC1 or anti–CD19-MUC1 conjugates in the presence or absence of CpG twice at a 2-week interval. PBS-immunized mice were used as control. At day 21, immunized mice were challenged with 5 × 104 RAM-MUC1 tumor cells subcutaneously. Tumor growth was recorded twice a week. (B) Data suggest that mice immunized with anti–CD19-MUC1 conjugates plus CpG achieved significant long-term tumor-free survival. (C) MUC1 Tg mice were inoculated subcutaneously with 5 × 105 RAM-MUC1 tumor cells. After 7 days, mice were immunized as described in panel A. Tumor growth was recorded twice a week. Error bars show SEM. (D) Long-term tumor-free survival at day 50.
